Le informazioni sugli articoli di fonte ISI sono coperte da copyright

Per ulteriori informazioni selezionare i riferimenti di interesse.

1. Depatie, L; Lal, S
   Apomorphine and the dopamine hypothesis of schizophrenia: a dilemma?
   JOURNAL OF PSYCHIATRY & NEUROSCIENCE
   
   L. Depatie e S. Lal, "Apomorphine and the dopamine hypothesis of schizophrenia: a dilemma?", J PSYCH NEU, 26(3), 2001, pp. 203-220
2. Contin, M; Riva, R; Albani, F; Baruzzi, A
   Pharmacokinetic optimisation of dopamine receptor agonist therapy for Parkinson's disease
   CNS DRUGS
   
   M. Contin et al., "Pharmacokinetic optimisation of dopamine receptor agonist therapy for Parkinson's disease", CNS DRUGS, 14(6), 2000, pp. 439-455
3. Poewe, W; Wenning, GK
   Apomorphine: An underutilized therapy for Parkinson's disease
   MOVEMENT DISORDERS
   
   W. Poewe e G.K. Wenning, "Apomorphine: An underutilized therapy for Parkinson's disease", MOVEMENT D, 15(5), 2000, pp. 789-794
4. CORBOY DL; WAGNER ML; SAGE JI
   APOMORPHINE FOR MOTOR FLUCTUATIONS AND FREEZING IN PARKINSONS-DISEASE
   The Annals of pharmacotherapy
   
   D.L. Corboy et al., "APOMORPHINE FOR MOTOR FLUCTUATIONS AND FREEZING IN PARKINSONS-DISEASE", The Annals of pharmacotherapy, 29(3), 1995, pp. 282-288
5. MUGUET D; BROUSSOLLE E; CHAZOT G
   APOMORPHINE IN PATIENTS WITH PARKINSONS-DISEASE
   Biomedicine & pharmacotherapy
   
   D. Muguet et al., "APOMORPHINE IN PATIENTS WITH PARKINSONS-DISEASE", Biomedicine & pharmacotherapy, 49(4), 1995, pp. 197-209
6. GANCHER S
   PHARMACOKINETICS OF APOMORPHINE IN PARKINSONS-DISEASE
   Journal of neural transmission. Supplementum
   
   S. Gancher, "PHARMACOKINETICS OF APOMORPHINE IN PARKINSONS-DISEASE", Journal of neural transmission. Supplementum, (45), 1995, pp. 137-141
7. DURIF F; BEYSSAC E; COUDORE F; PAIRE M; ESCHALIER A; AIACHE M; LAVARENNE J
   COMPARISON BETWEEN PERCUTANEOUS AND SUBCUTANEOUS ROUTES OF ADMINISTRATION OF APOMORPHINE IN RABBIT
   Clinical neuropharmacology
   
   F. Durif et al., "COMPARISON BETWEEN PERCUTANEOUS AND SUBCUTANEOUS ROUTES OF ADMINISTRATION OF APOMORPHINE IN RABBIT", Clinical neuropharmacology, 17(5), 1994, pp. 445-453
8. COLOSIMO C; MERELLO M; ALBANESE A
   CLINICAL USEFULNESS OF APOMORPHINE IN MOVEMENT-DISORDERS
   Clinical neuropharmacology
   
   C. Colosimo et al., "CLINICAL USEFULNESS OF APOMORPHINE IN MOVEMENT-DISORDERS", Clinical neuropharmacology, 17(3), 1994, pp. 243-259
9. TOLOSA ES; VALLDEORIOLA F; MARTI MJ
   NEW AND EMERGING STRATEGIES FOR IMPROVING LEVODOPA TREATMENT
   Neurology
   
   E.S. Tolosa et al., "NEW AND EMERGING STRATEGIES FOR IMPROVING LEVODOPA TREATMENT", Neurology, 44(7), 1994, pp. 190000035-190000044
10. LEES AJ
    DOPAMINE AGONISTS IN PARKINSONS-DISEASE - A LOOK AT APOMORPHINE
    Fundamental and clinical pharmacology
    
    A.J. Lees, "DOPAMINE AGONISTS IN PARKINSONS-DISEASE - A LOOK AT APOMORPHINE", Fundamental and clinical pharmacology, 7(3-4), 1993, pp. 121-128
11. MONTASTRUC JL; RASCOL O; SENARD JM
    CURRENT STATUS OF DOPAMINE AGONISTS IN PARKINSONS-DISEASE MANAGEMENT
    Drugs
    
    J.L. Montastruc et al., "CURRENT STATUS OF DOPAMINE AGONISTS IN PARKINSONS-DISEASE MANAGEMENT", Drugs, 46(3), 1993, pp. 384-393